Medical Crossfire®: Closing Clinical Practice Gaps in Hepatobiliary Cancer With Emerging Immunotherapies and Delivery Innovations

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Ghassan Abou-Alfa, MD, JD, MBA, PhD (hc), Riad Salem, MD, MBA, Rachna T. Shroff, MD, MS, FASCO, and Arndt Vogel, MD, PhD discuss closing clinical practice gaps in hepatobiliary cancer with emerging immunotherapies and delivery innovations.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Evaluate clinical evidence on the safety and efficacy of new immunotherapy approaches for the treatment of hepatobiliary cancers across diverse patient populations
• Integrate the latest evidence and expert guidance into personalized treatment plans for patients with hepatocellular and biliary tract cancers
• Apply multidisciplinary best practices to optimize coordination, continuity, and quality of care for patients with hepatobiliary cancers

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals.

Chair:

Ghassan Abou-Alfa, MD, JD, MBA, PhD (hc)

Professor of Medicine
Weill Cornell Medical College at Cornell University
Attending Physician
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AbbVie, Alligator Bioscience, AstraZeneca, Autem Therapeutics, Berry Genomics, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Eisai, Exelixis, Genentech/Roche, Incyte, Ipsen, J-Pharma, Merck, Merus, Neogene Therapeutics, Novartis, Servier, Tango Therapeutics, Tempus, Vector Pharma, Yiviva; Grant/Research Funding: Agenus, Arcus, AstraZeneca, BioNTech, Bristol Myers Squibb, Elicio Therapeutics, Genentech/Roche, Helsinn, Parker Institute, Pertzye, Puma, QED Therapeutics, Servier, Yiviva.

Faculty:

Riad Salem, MD, MBA

Professor of Radiology, Medicine, and Surgery
Vice-Chair, Image-Guided Therapy
Department of Radiology
Northwestern University
Chicago, IL

Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AstraZeneca, Bard, Boston Scientific, Cook, Eisai, Genentech, Siemens, Sirtex Medical, Trisalus Life Sciences, Inc.

Rachna T. Shroff, MD, MS, FASCO

Professor, Department of Medicine
John and Valli Duval Endowed Professor in Gastrointestinal Oncology
Chief, Division of Hematology/Oncology
University of Arizona College of Medicine—Tucson
Associate Director of Clinical Investigations
University of Arizona Cancer Center
Tucson, AZ

Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AstraZeneca, Elevar Therapeutics, Genentech, ICON Clinical Research LLC.

Arndt Vogel, MD, PhD

Professor of Medicine, University of Toronto
Longo Family Chair in Liver Cancer Research
Clinician Scientist
Division of Gastroenterology and Hepatology, Toronto General Hospital
Medical Oncology, Princess Margaret Cancer Centre
Toronto General Hospital Research Institute
Schwartz Reisman Liver Research Centre
Institute for Medical Science
Toronto, Canada

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, AstraZeneca, Biologix, Boehringer Ingelheim, Bristol Myers Squibb, Cogent, Eisai, Elevar, Incyte, Ipsen, Janssen, Jazz Pharmaceuticals, Lilly, Medivir, MSD, Roche, Servier, Taiho, Terumo, Tyra, Zymeworks.

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including information oninformation on combining locoregional and systemic therapies for hepatocellular carcinoma and the latest immunotherapy approaches for biliary tract cancer, go to https://www.gotoper.com/courses/medical-crossfire-closing-clinical-practice-gaps-in-hepatobiliary-cancer-with-emerging-immunotherapies-and-delivery-innovations-h754.

Release Date

July 13, 2026

Expiration Date

July 13, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.